Amarin's Vascepa goes on TV to lay groundwork for impending CV outcomes data

Amarin's heart drug Vascepa is casting its net with a first-ever TV ad campaign. Although the triglyceride-lowering drug has been on the market for five years, Amarin is anticipating cardiovascular outcomes data this fall—and if the trial comes up positive as hoped, the company wants to be ready to go.